Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical impact of a pre-screening system using comprehensive genomic profiling to guide phase I trial registry in patients with advanced solid tumors


21 Dec 2015


Basic Science, biomarkers, new diagnostics and translational research


Hitomi Okuma


Annals of Oncology (2015) 26 (suppl_9): 148-152. 10.1093/annonc/mdv533


H.S. Okuma1, Y. Tanabe1, H. Ichikawa2, T. Kohno3, H. Yoshida4, T. Kubo5, A. Shimomura6, S. Iwasa6, S. Kondo6, S. Kitano6, Y. Fujiwara6, N. Yamamoto6, K. Tamura1

Author affiliations

  • 1 Department Of Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Division Of Genetics, National Cancer Center Research Institute, 104-0045 - Tokyo/JP
  • 3 Division Of Genome Biology, National Cancer Center Research Institute, 104-0045 - Tokyo/JP
  • 4 Department Of Pathology And Clinical Laboratories, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 5 Division Of Translational Research, Exploratory Oncology Research & Clinical Center, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 6 Department Of Experimental Therapeutics, Exploratory Oncology Research & Clinical Center, National Cancer Center Hospital, 104-0045 - Tokyo/JP



Molecular targeted therapies have clinical benefit on patients with specific molecular alterations. We hypothesized that on enrolling patients in phase I clinical trials, a pre-screening system using next generation sequencing (NGS), to identify molecularly “matched” patients, would increase response rate and accelerate drug development.


We prospectively recruited patients with solid tumors candidates for phase I trials at the National Cancer Center Hospital in Japan. Genomic sequencing was performed on archival tissue samples using an original oncogene panel “NCC oncopanel” (90 mutations/amplifications and 10 fusion genes). On the basis of the identified genetic alterations, a multidisciplinary team interpreted the gene profile and selected a suitable ongoing phase I trial. Primary endpoint was proportion of patients registered in phase I trials after the molecular characterization. Secondary endpoint was proportion of patients treated with the “matched” molecular targeted drugs.


From July 2013 to October 2014, 183 patients with breast, gastric, ovarian, lung, and 5 other cancer types were enrolled. Sequencing was performed in 131 (72%) of all patients. An average of 1.93 mutations and 0.29 amplifications per patient were identified. Of 131 patients, 59 (45%) patients had at least one actionable altered gene, and alterations were found most frequently in breast cancer patients. Altered genes included PIK3CA (15 patients), CCND1 (12 patients), BRCA2 (9 patients), and BRCA1 (3 patients). 28 (21%) entered phase I trials, 11 (8.4%) underwent therapy with the “matched” drug. Of the patients treated with the “matched” drug, 3 showed objective response, and 3 had stable disease.


NGS-based molecular pre-screening is a feasible and potent useful platform before registrating patients in a phase I clinical trial.

Clinical trial identification



All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings